Clinical Trial Update: A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating tolerability, safety, and pharmacokinetics of intravenous INO-1001 combined with oral temozolomide in patients with melanoma; the tri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• INO-1001 (PARP inhibitor)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Genentech, Inc. | Conditions: Melanoma | Phase 1 | Status: TERMINATED